Immediate Impact
51 standout
Citing Papers
Polymeric Nanoparticles for Drug Delivery
2024 Standout
Cancer statistics, 2023
2023 Standout
Works of James E. Delmore being referenced
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
2015
Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study
2003
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| James E. Delmore | 132 | 172 | 241 | 146 | 25 | 506 | |
| Ron E. Swensen | 178 | 146 | 213 | 180 | 29 | 529 | |
| Norman G. Rosenblum | 117 | 168 | 244 | 98 | 43 | 547 | |
| Marina Stasenko | 94 | 201 | 122 | 107 | 34 | 512 | |
| L. Chauvenet | 180 | 81 | 209 | 270 | 18 | 514 | |
| Giuseppe Scibilia | 131 | 130 | 215 | 71 | 45 | 485 | |
| Amelia Jernigan | 149 | 182 | 167 | 137 | 46 | 437 | |
| Amy L. Gross | 46 | 147 | 280 | 150 | 14 | 520 | |
| Samith Sandadi | 144 | 281 | 222 | 84 | 18 | 536 | |
| Robin A. Lacour | 57 | 154 | 191 | 180 | 21 | 567 | |
| J. Einenkel | 73 | 230 | 142 | 125 | 35 | 509 |
All Works
Loading papers...